BPC-157 Research Summary BPC-157 was first described by the Sikiri research group at the University of Zagreb in 1991-1993 as a fragment of a putative ~40 kDa 'body protection compound' protein isolated from human gastric juice [6]
The mechanisms underlying its hepatotoxic effects involve mitochondrial dysfunction, oxidative stress, and the inhibition of the bile salt export pump, resulting in the accumulation of toxic bile salts within hepatocytes [39]
Diabetes Metab Syndr Obes Targets Ther
Because pyridoxine HCl Injection is a water-soluble vitamin preparation, it does not typically cause systemic toxicity at recommended dosages
The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer
Over 80% of compounded semaglutide and tirzepatide prescriptions now include supplemental ingredients such as B vitamins (B6, B12, B3) or levocarnitine